Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 5,923 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more

Conditions: Myelodysplastic Syndrome
Interventions: ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Tampa, Florida • New York, New York

Conditions: Cow's Milk Allergy
Interventions: Baked non-fat cow's milk powder, Placebo: Tapioca Powder; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson's Disease
Interventions: PARCOPA; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Timeline: 2004
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Iron Deficiency Anemia
Interventions: Ferric carboxymaltose; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Miami Springs, Florida

Conditions: Dysphagia of Newborn
Interventions: Pacifier-Activated Lullaby (PAL) Therapy; Device
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 34 Weeks to 36 Weeks
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Digoxin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Davie, Florida • Chicago, Illinois • Boston, Massachusetts

Conditions: Anemia
Interventions: Ferric Carboxymaltose (FCM), Ferrous Sulfate tablets; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Impairment of Oral Perception, Insulin Resistance
Interventions: Sucralose, Sucrose, Sucralose + maltodextrin, Sucralose + Sucrose; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 23 Years to 45 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: VZV Infection After Bone Marrow Transplantation
Interventions: Acyclovir; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1985 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes, Insulin Resistance
Interventions: Exercise; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 30 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy Volunteer, Urea Cycle Disorder
Interventions: Placebo, SYNB1020; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Hyperkalemia
Interventions: Patiromer Powder for Oral Suspension [Veltassa], Placebo; Drug
Lead sponsor: Comprehensive Research Associates; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 28
States / cities: Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 11
States / cities: Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more

Conditions: Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Pregnancy-Induced Hypertension in Postpartum, Hypertensive Emergency
Interventions: Labetalol, Nifedipine; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer, Dysgeusia, Oral Complications of Chemotherapy
Interventions: questionnaire administration, quality-of-life assessment, laboratory biomarker analysis, bovine lactoferrin; Other · Procedure · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Xerostomia
Interventions: 3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray, Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray; Device
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Heart Failure
Interventions: Dapagliflozin 10mg Tab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Viral Infection
Interventions: UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg, UV-4B 90 mg, UV-4B 180 mg, UV-4B 360 mg, UV-4B 720 mg, UV-4B 1000 mg, Placebo; Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Dentin Sensitivity
Interventions: Stannous fluoride; Other
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 536 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome
Interventions: nalbuphine plus naloxone, nalbuphine plus placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Cancer
Interventions: Capecitabine, Oxaliplatin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gingival Recession
Interventions: Gingival graft surgery to treat gingival recession; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

Baked Milk Oral Immunotherapy for Cow's Milk Allergy

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

The Effects of Pacifier-Activated Lullaby on Oral Feeding Among Preterm Infants

Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes

Safety and Tolerability of SYNB1020-CP-001

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

Postpartum Hypertension Study

Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy

Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray

The Fontan Dapagliflozin Pilot Study

Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

A Real-World Evidence Study Evaluating Oral Health Related Quality Of Life With Use Of A Stannous Fluoride Anti-Sensitivity Toothpaste For Dentin Hypersensitivity Management

Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain

Title XELOX FOR SALIVARY GLAND CANCERS

Taking Measurements of a Gum Graft Site as it Heals